Thursday, October 21, 2021 10:21:46 PM
Recent KTRA News
- Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones • PR Newswire (US) • 07/01/2024 12:35:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 06/13/2024 08:10:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:05:11 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 06/03/2024 12:50:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 12:45:11 PM
- TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) • PR Newswire (US) • 06/03/2024 12:35:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/17/2024 08:10:11 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/17/2024 08:05:37 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 05/14/2024 08:55:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:50:14 PM
- Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results • PR Newswire (US) • 05/14/2024 08:45:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:40:36 PM
- Form S-4 - Registration of securities, business combinations • Edgar (US Regulatory) • 05/13/2024 08:06:50 PM
- Kuehn Law Encourages KTRA, ABIO, SWAV, and NS Investors to Contact Law Firm • PR Newswire (US) • 04/05/2024 05:09:00 PM
- Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement • PR Newswire (US) • 04/03/2024 11:00:00 AM
- Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab • PR Newswire (US) • 03/27/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 11:59:49 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:00:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 12:00:10 PM
- Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update • PR Newswire (US) • 02/14/2024 09:07:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 02:05:27 PM
- Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer • PR Newswire (US) • 02/12/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 09:10:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/18/2023 09:05:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2023 09:15:08 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM